Peripheral CD4+ cell prevalence and pleuropulmonary manifestations in systemic lupus erythematosus patients  by Vincze, Krisztina et al.
Respiratory Medicine (2014) 108, 766e774Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedPeripheral CD4D cell prevalence and
pleuropulmonary manifestations in systemic
lupus erythematosus patients
Krisztina Vincze a,1, Zsuzsanna Kovats a,1, Aron Cseh b,
Krisztina Pasti b, Emese Kiss c, Anna Polgar c, Barna Vasarhelyi b,
Attila J. Szabo b, Aniko Bohacs a, Lilla Tamasi a,
Gyo¨rgy Losonczy a, Veronika Mu¨ller a,*a Department of Pulmonology, Semmelweis University, Dios arok 1/c, Budapest 1125, Hungary
b I.st Department of Pediatrics, Semmelweis University, Bokay J u. 53, Budapest 1083, Hungary
c National Institute of Rheumatology and Physicotherapy, Frankel Leo u. 25-29,
Budapest 1023, HungaryReceived 24 October 2013; accepted 10 February 2014
Available online 18 February 2014KEYWORDS
Systemic lupus
erythematosus;
Lung;
Lung function;
T cells;
CD4þCD25hiþ* Corresponding author. Tel.: þ36 1
E-mail address: mulver@pulm.sote
1 First and second author contribute
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease involving several
organs, including the lungs. Previous results confirmed changes of peripheral T cell subsets in
lupus patients; however no data are available about their possible relationship with pulmonary
involvement.
Objective: To determine pulmonary manifestations and potential relationship in changes of
peripheral CD4þ T cell subsets.
Methods: Patients with SLE (N Z 28) were enrolled in complex pulmonary examination. Pa-
tients were divided into groups with pleuropulmonary manifestations (SLEpulm N Z 13 age:
44.9  3.3 years, female: maleZ 11:2) or without (SLEc NZ 15 age: 27.2  3.7 years, female:
male Z 12:3). Peripheral blood was taken for T helper (Th)1, Th2, Th17, CD4þCD25hiþ and
regulatory T (Treg: CD4þCD25hiþ CD127) cell analysis from SLE patients and healthy volun-
teers (controls, N Z 40).
Results: SLEpulm patients were older, had more pulmonary symptoms and significantly
decreased pO2 as compared to SLEc group. Ventilatory disorder was present in 92% of SLEpulm
patients, with significantly decreased lung volumes, signs of airway involvement and decrease
in DLco. Significant increase in Th1/Th2, while decrease in Th17/Treg ratios was present in all
SLE compared to controls. In SLEpulm CD4þCD25hiþ subset without changes in Treg number was3559733; fax: þ36 1 2142498.
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Peripheral CD4þ T cells and lung manifestation of SLE 767significantly increased as compared to SLEc and this subgroup of T cell showed significant pos-
itive correlation with dynamic lung function parameters and DLco (p < 0.05).
Conclusion: In lupus patients pleuropulmonary manifestations are prevalent and lung function
and blood gas measurements should be regularly performed in the daily clinical assessment.
Significant increase of activated CD4þCD25hiþ T cells, but not Treg is associated with
decreased lung function parameters in SLEpulm patients.
ª 2014 Elsevier Ltd. All rights reserved.Table 1 Prevalence of ACR classification criteria in SLEc
(N Z 15) and SLEpulm (N Z 13) patients.
ACR criteria SLEc N (%) SLEpulm N (%)
Malar rash 10 (67)* 3 (23)
Discoid rash 2 (13) 2 (15)
Photosensitivity 11 (73)* 5 (38)
Oral ulcers 4 (27) 2 (15)
Arthritis 11 (73) 9 (69)
Serositis 5 (33) 5 (38)
Renal disorder 9 (60)* 3 (23)
Neurologic disorder 5 (33) 2 (15)
Hematologic disorder 10 (67) 9 (69)
Immunologic disorder 14 (93) 9 (69)
Antinuclear antibody 15 (100) 12 (92)#
Values are number positive (%), #data missing from 1 patient,
SLEpulm: SLE pleuropulmonary manifestation group, SLEc: SLE
without pleuropulmonary manifestation group; *: p < 0.05 vs.
SLEpulm.Introduction
Systemic lupus erythematosus (SLE) is characterized by the
presence of autoantibodies and immuncomplexes targeting
multiple organs, including skin, joints, kidneys, small ves-
sels and central nervous system. SLE may also affect the
pleura and the lungs. According to the affected area pul-
monary manifestations include pleuritis, parenchyma
destruction, airway disease, vascular or musculoskeletal
involvement.
Most often SLE subjects will present with pleuritis
(35e50%), which is part of the American College of Rheu-
matology (ACR)diagnostic criteria [1,2]. It is often asymp-
tomatic but may be accompanied by non-productive cough,
dyspnea or thoracic pain. Various studies have shown that
high resolution computer tomography (HRCT) reveals
interstitial lung disease (ILD) at least in a third of partly
asymptomatic SLE subjects, suggesting that subclinical
lung disease is even more common in these patients [3].
Adult respiratory distress syndrome (ARDS) may occur in
5e15% of patients [4]. Rare, but clinically severe pulmonary
manifestations are diffuse alveolar hemorrhage (1e5%)
and acute lupus pneumonitis (1e4%) [5]. Pulmonary
arterial hypertension due to SLE has been identified in
approximately 4% of subjects, but is present in 75% in pa-
tients with Raynaud’s syndrome [6,7]. Shrinking lung syn-
drome, although a lesion of diaphragmatic origin, severely
affects lung function and is more prevalent than thought
formerly [8].
Concerning airway involvement, only sparse data are
available. Bronchial wall thickening and bronchiectasis are
present in approximately 20% of subjects with SLE, but it is
considered frequently clinically irrelevant. Obliterative
bronchiolitis has rarely been described [9]. Reductions in
the forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC) ratio and forced expiratory flow rate
between 25% and 75% of FVC (FEF25e75) were detected in
relative high proportion (5.7e24%) of patients, consistent
with small airways disease [10,11].
Although evidence is growing on pathomechanism of
systemic autoimmun diseases with multiple manifestations,
there is large variance in details. Systemic review of pul-
monary manifestations is rare, and possible clinical impli-
cations of more accurate observations are missing.
Imbalance of T-helper (Th) cell differentiation and sub-
sequent cytokine dysregulation is implicated in inflamma-
tory and autoimmune diseases. Elevated ratio of Th1/Th2
cytokines correlates positively with disease activity in SLE
patients [12,13]. Hoyer and colleagues suggests that Th1
cells drive the early autoantibody response in systemic
autoimmune disease [14].Regulatory T (Treg) cells are playing a critical role in the
maintenance of self-tolerance by preventing the activation
and function of effector T cells [15,16]. Disturbances in
number and suppressive capacity of Treg cells are thought
to have a role in development and activity of SLE
[17,18,19]. Additionally, activated Treg cells are involved in
differentiation of interleukin (IL)-17 producing Th17 cells
[20]. Th17 cells are implicated in chronic inflammatory
processes, however only few data are available relating to
SLE [21,22]. IL-17 produced by Th17 cells may play a role in
the amplification and perpetuation of the inflammatory
response in organs targeted by SLE [23].
Despite the high prevalence of pleuropulmonary ab-
normalities which often result in remarkable loss of
quality of life and are important causes of SLE mortality,
we know little about the mechanisms leading to the
development of lung manifestations. In this study we
aimed to determine a practical and useful clinical
approach for screening pulmonary involvement in SLE.
Additionally, differences in peripheral Th1, Th2, Treg and
Th17 cell prevalence among patients with and without
pleuropulmonary involvement and all SLE patients to
healthy controls were analyzed.
Methods
Study subjects included 28 SLE patients with mean age of
35.4  2.9 (mean  SEM, range 11e64 years) years who
were referred to the Department of Pulmonology for
pleuropulmonary involvement screening from the Ist
Table 3 Prevalence of chest complaints and blood gas
parameters in SLEc (NZ 15) and SLEpulm (NZ 13) patients.
Complaints SLEc SLEpulm
Effort dyspnea (N) 1 (7%)* 11 (85%)
Cough (N) 2 (13%) 5 (38%)
Chest pain (N) 1 (7%) 4 (31%)
pH 7.431  0.008 7.460  0.008
pCO2 (mmHg) 29.85  0.38 30.23  0.53
pO2 (mmHg) 92.73  2.28* 70.23  3.51
Actual HCO3
 (mmol/l) 20.21  0.38 21.82  0.48
Values are number positive (%); *: p < 0.05 vs. SLEpulm.
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All patients fulfilled the updated ACR criteria for the clas-
sification of SLE (Table 1) [24]. Disease activity was scored
based on the SLE disease activity index (SLEDAI) [25]. Pa-
tient characteristics are listed in Table 2. All patients
received immunosuppressive treatment.
Patients were asked for respiratory symptoms, under-
went physical examination, chest X-ray, electrocardiog-
raphy and routine laboratory analysis. FVC, FEV1, FEV1/
FVC, flow volume curves, FEF25e75 and airway resistance
(Raw) were measured by means of electronic spirometer
and pletysmography (PDD-301/s, Piston, Budapest,
Hungary) according to the American Thoracic Society
guidelines [26]. Three technically acceptable maneuvers
were performed and the highest of them was used. Carbone
monoxide diffusing lung capacity (DLco) was measured with
single breath method. Pulmonary function variables were
expressed as percentage of predicted values. Arterialized
capillary blood gases, pH and bicarbonate levels were
analyzed at rest at room air (Stat Profile pHOx Plus, Nova
Biomedical Corporation, Waltham MA, USA).
Peripheral blood was taken from 22 SLE patients at the
time of pulmonary screening (age 32.7  3.5 years (range:
11e64 years), female/male:17/5, Table 2) and from a
population samples of 40 healthy blood donor adults (age
35.5  5.6 years (range: 20e70 years), female/male: 36/4)
for T cell analysis. All cases and controls were of Caucasian
ethnic origin. The study was reviewed and approved by the
ethics committee of the Department of Pulmonology.
Peripheral T cell subpopulations were analyzed using 6 ml
sodium heparinized venous blood. Peripheral blood mono-
nuclear cells were isolated and frozen at 80 C. Identifi-
cation of surface markers (CD3, CD4, CD8, CD25, CD127;
CXCR3, CCR4, CCR6, BD Biosciences Pharmingen, San Diego,
CA, USA) were performed with a BD FACS Aria according to
manufacturer’s protocols as from isolated PBMC-s described
previously [27]. Th1 cells were identified by CD4þCXCR3þ,
while Th2 cells by CD4þCCR4 positivity [28]. For theTable 2 Patient characteristics and immunosuppressive medica
All SLE patients (N Z
Characteristic SLEc N Z 15
Age (years) 27.2  3.7*
Gender (female:male) 12:3
BMI (kg/m2) 22.0  1.3
Age at onset, years 19.3  3.1*
Time from diagnosis, years 7.9  1.8
Smoker (N ) 2 (13%)*
SLEDAI (>3) (N ) 3 (20%)*
Immunosuppressive medication (N ) 15 (100%)
Systemic corticosteroid (N ) 8 (53%)*
Methylprednisolon dose (mg/day) 3.6  1.9*
Methotrexat (N ) 2 (13%)
Cyclophosphamid (N ) 5 (33%)
Azathioprin (N ) 6 (40%)*
No significant differences between all patient groups and patient
mean  SEM. SLEpulm: SLE pleuropulmonary manifestation group SLEc:
SLEpulm.detection of Treg cells CD4þCD25hiþ positivity accompanied
by low expression of CD127 was used [29], additionally
CD4þCD25hiþ cells were also measured. Th17 cells were
characterized by CD4þCCR4þ and CCR6þ surface markers
[30]. All CD4þ T cell numbers are expressed in G/L accord-
ingly to patients absolute lymphocyte count.
Data are reported as means  SEM. Statistical analysis
was performed with GraphPad software (Graph Pad Prism
5.0 by Graph Pad Software Inc., San Diego, USA). Normally
distributed data were analyzed by unpaired t-test and
ANOVA. After one-way ANOVA, if significant difference
(p < 0.05) was found, the NewmaneKeuls multiple com-
parison post-hoc test was used for further analysis. Cate-
gorical data were analyzed by c2 or Fisher’s exact test.
Parametric data were compared using Student’s t-test.
p < 0.05 was considered statistically significant.
Results
Pulmonary manifestations
Patients in the SLEpulm group were significantly older than
SLEc patients; however duration of the disease did not
differ between groups. SLEpulm patients were more likely totion.
28) SLE patients with T cell analysis
(N Z 22)
SLEpulm N Z 13 SLEc N Z 13 SLEpulm N Z 9
44.9  3.3 24.8  3.7* 44.0  4.7
11:2 10:3 7:2
23.5  0.9 21.5  1.3 22.8  1.0
36.9  2.9 17.9  2.9* 37.2  4.0
7.0  2.4 7.0  1.7 5.9  2.7
6 (46%) 2 (15%)* 4 (44%)
11 (85%) 2 (15%)* 8 (89%)
13 (100%) 13 (100%) 9 (100%)
12 (92%) 7 (54%)* 8 (89%)
15.4  2,8 2.0  0.7* 15.6  3.3
3 (23%) 2 (15%) 3 (33%)
8 (61%) 4 (30%) 5 (55%)
2 (15%) 5 (38%)* 1 (11%)
s with T cell analysis groups were found. Values are given in
SLE without pleuropulmonary manifestation group; *p < 0.01 vs.
Figure 1 Prevalence of pulmonary manifestations at the time of pulmonary examinations in SLEc and SLEpulm patients. Pulmonary
embolism represents patients on continuous anticoagulant treatment as the result of previously confirmed pulmonary embolism.
*p < 0.0001 vs. SLEpulm group.
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did differ significantly in the daily steroid use, as patients in
the SLEpulm had higher doses as SLEc patients. Azathioprin
was more commonly used as compared to other immuno-
suppressive agents in SLEc.
SLEpulm patients had significantly more pulmonary com-
plaints than their SLEc counterparts (Table 3). Dyspnea was
the leading symptom in SLEpulm and was associated with
significantly decreased pO2 in these patients. The preva-
lence of different pulmonary manifestations in all SLE pa-
tients is shown in Fig. 1. Significantly increased number of
serositis, shrinking lung, pulmonary vascular diseases were
noted in SLEpulm patients, however it was the most pro-
nounced in respect to lung function abnormalities (SLEpulm:
92% vs. SLEc: 33%, p < 0.0001) and fibrosis (SLEpulm: 54% vs.
SLEc: 0%, p < 0.0001). Two patients in the SLEc group wereFigure 2 Distribution of lung function abnormalities in SLformerly treated as a result of interstitial lung disease,
however had no signs of pulmonary involvement at the time
of analysis. Most patients (69%) had restrictive and mixed
type, whereas one fifth in both groups dominantly mild
obstructive ventilatory disorder (Fig. 2). Although the mean
values for lung function parameters were within the normal
range in SLEc group, decreased FEF25e75 and increase in
Raw values indicated incipient small airway disease in some
of these patients and were regarded as obstructive venti-
latory disorder in this group. Significantly decreased values
in the SLEpulm group compared to SLEc were measured for
FVC, FEV1 and FEF25e75 (Fig. 3). DLco (96.7  4.1 vs.
61.8  5.1% predicted, p < 0.01) and lung volume adjusted
KLCO (102.9  7.1 vs. 72.5  3.4% predicted, p < 0.01) were
significantly lower in the SLEpulm than in the SLE c patient
group (Fig. 3).Ec and SLEpulm patients (p Z 0.0018 vs. SLEpulm group).
Figure 3 Pulmonary function parameters in SLEc and SLEpulm patients. Mean values  SEM of forced vital capacity (FVC % pre-
dicted), forced expiratory volume in one second (FEV1 % predicted), forced expiratory flow (FEF25e75% predicted) and DLco.
*p < 0.05 vs. SLEpulm group.
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As a marker of the disease significantly decreased absolute
number of lymphocytes was noted in all SLE patients
(SLEpulm: 1.55  0.36 G/L; SLEc: 1.19  0.17 G/L; control:
2.14  0.10 G/L; p < 0.05 vs. both SLE groups). To avoid
changes resulting from change in lymphocyte number not
prevalence but absolute number of respective CD4þ cell
populations were analyzed.
No change in absolute circulating number of Th1 cells
was measured in SLE patients while significantly decreased
number of Th2 cells resulted into elevated Th1/Th2 ratio as
compared to controls. There was no difference between
SLEpulm and SLEc subgroups in respect to Th1, Th2 cells or
Th1/Th2 ratio (Table 4. Fig. 4(A)).
Significant decrease in Th17 and Treg (CD4þCD25hiþ
CD127) was present in SLE patients as compared to con-
trols, without differences according lung involvement
(Table 4). Interestingly, Th17/Treg ratio was also lower in
lupus patients as in healthy subjects (Fig. 4(B)). Additional
analysis using CD4þCD25hiþ positive cells revealed signifi-
cantly increased cell number in SLEpulm compared to SLEc or
controls (Table 4). Similarly decreased relative proportion
of Treg in CD4þCD25hiþ cells in SLEpulm to SLEc and controlsTable 4 Prevalence peripheral CD4þ T lymphocytes in SLE c (
(N Z 40) patients.
SLEc
Th1 (CD4þCXCR3þ) G/L 0.655  0.108
Th2 (CD4þCCR4þ) G/L 0.023  0.005#
Th17 (CD4þCCR4þCCR6þ) G/L 0.012  0.003#
CD4þCD25hiþ G/L 0.034  0.007*
Treg (CD4þCD25hiþ CD127) G/L 0.030  0.006#
SLEpulm: SLE pleuropulmonary manifestation group; SLEc: SLE witho
#p < 0.05 vs. control.suggests pleuropulmonary specific increase of other, non
“real” Treg cell in SLEpulm probably representing an other
subgroup of activated T cells (Fig. 4(C)).
Analyzing relationship between lung function parame-
ters in SLE patients and differences in peripheral Th1, Th2
Th17 or Treg cell subsets no association was observed. In
contrast significant association was demonstrated regarding
static and dynamic lung function parameters (FVC, FEV1) or
DLco and CD4þCD25hiþ or Treg/CD4þCD25hiþ ratio. This is
further emphasizing a possible lung specific CD4þCD25hiþ
T cell subset, not incorporating “real” Tregs (Fig. 5).
Discussion
In our analysis high prevalence of lung manifestations in
SLE patients was observed. This is in accordance with a
recent analysis [8] but higher than detected in earlier
studies [2], maybe partly due to patient selection bias, as
specific interest on pulmonary manifestation might have
resulted in enrollment of more patients with pulmonary
complaints. This can influence some of our results e e.g.
on correlation between lung manifestations and disease
activity e but also allows a more detailed examination of
this entity. The most prevalent pulmonary dysfunctionN Z 13) and SLEpulm (N Z 9), all SLE (N Z 22) and control
SLEpulm All SLE Control
0.846  0.199 0.731  0.102 0.865  0.069
0.023  0.006# 0.023  0.004# 0.138  0.015
0.023  0.006# 0.016  0.003# 0.067  0.007
0.218  0.046# 0.108  0.027 0.093  0.008
0.032  0.012# 0.031  0.005# 0.056  0.005
ut pleuropulmonary manifestation group; *p < 0.05 vs. SLEpulm;
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rameters (FVC, FEV1) often also accompanied by changes
reflecting small airway dysfunction (FEF25e75) and dimin-
ished diffusion capacity (DLco). Changes in lung function
were observed even without abnormalities on chest X-ray,
fluoroscopy or HRCT. Regarding the notably higher pro-
portion of functional than radiological changes among
patients, we confirmed recent results from Allen et al. [8]
stating that lung function testing is fundamental in
screening for lung manifestations in SLE. Additionally to
the leading symptoms of dyspnea blood gas analysis can
substantiate lung involvement as SLEpulm patients had
significantly decreased pO2 values.
In our cohort of SLE patients significant decrease in the
absolute number of Th2 cells without change in Th1 cells
resulted in elevated Th1/Th2 as compared to controls
irrespective of lung involvement. Similarly, significantly
lower Th17 and Treg cell proportions were found in patients
with SLE disease. Although investigations of different pe-
ripheral CD4þ T cell subsets according to disease activity
were performed results remain controversial. Previous in-
vestigations confirmed increase in Th1/Th2 ratio in pe-
ripheral blood of SLE patients associated with disease
activity [12], while Chang et al. did not show association
between higher Th1/Th2 ratio and SLEDAI score [31]. Th1
cells seem to drive the early autoantibody response [14]
and increase in Th1 cytokines might promote lung fibrosis
[32]. In our study all lupus patients had decreased
lymphocyte count, so absolute numbers of T cells were
analyzed. This revealed that the absolute number of Th1
cells was similar to controls, while Th2 decrease contrib-
uted to the increase in Th1/Th2 ratio in all SLE patients
without reflecting disease activity or pulmonary
involvement.Figure 4 (A): Th1/Th2; (B): Th17/Treg and (C): Treg/CD4þCD2
*p < 0.05 vs. SLEpulm; #p < 0.05 vs. control.Th17 cells are a new lineage of effector CD4þ T cells
that are characterized by their production of IL-17A. Most
analyses use IL-17 labeling, while recent studies confirmed
high CCR4 and CCR6 expression on CD4þ cells also corre-
sponding to Th17 cells [30,33,34]. Emerging data support
the importance of Th17 cells in inflammatory diseases
especially autoimmunity [35]. However, there are contro-
versial data on the number of Th17 cells in the periphery
and in the affected organs in lupus patients. Th17 cells and
microenvironmental IL-17A has been shown to be involved
in vascular inflammation in SLE [43]. Hoyer et al. suggested
that Th17 cells might be responsible for the persistent
(chronic) inflammation of the tissues in autoimmune
mediated inflammation [14]. Th17 derived cytokines
(dominantly IL-17) play an important role in lung inflam-
mation by mediating neutrophil recruitment [36]. In a mu-
rine model of hypersensitivity pneumonitis and lung fibrosis
higher number Th17 derived cytokines were expressed in
the lung tissue, however the source of the cytokines were
gdT and not Th17 cells [37]. In our SLE patients significantly
decreased peripheral Th17 cell number was noted as
compared to healthy controls, while no differences ac-
cording lung involvement were noted.
Treg cells might play an important role in the devel-
opment of autoimmunity. In our patients decreased Treg
number was observed in all SLE patients. The reported
findings on Treg cells in SLE are not consistent, however
most studies found decreased number of Treg cells in the
peripheral blood of SLE patients [17,38]. In addition to low
numbers, defects in suppressive capacity of Treg cells
might also contribute to development or increased activ-
ity of the disease [19,39]. In contrast, increase in Treg
cells was observed in SLE patients receiving corticoste-
roids which act via increase in Treg cell number or activity5hiþ cell ratio in SLEc, SLEpulm all SLE and control patients.
Figure 5 Correlation of lung function parameters and CD4þCD25hiþ cell number and Treg/CD4þCD25hiþ ratio in all SLE pa-
tients. A: FVC (% predicted); r Z 0.556, p Z 0.0109, B: FEV1 (% predicted); r Z 0.515, p Z 0.020, C: DLco (% predicted);
r Z 0.520, p Z 0.027.
772 K. Vincze et al.resulting in better disease control [22,40]. Nearly all of
our patients were on corticosteroid therapy, with signifi-
cantly higher doses administered in SLEpulm patients. Di-
versity in outcomes concerning Treg cells may result
partly from small subject number, different disease
phases, various therapy or heterogeneity of the disease
itself.
Although multiple types of Treg cells have been
described, Treg cells are dominantly characterized by thehigh expression of the activation surface marker CD25.
However, analyzing the CD4þCD25 þ lymphocyte subset
CD25 is not only expressed on Treg cells, but also on
recently activated T helper lymphocytes. The most widely
accepted key marker for the identification of true Treg
cells is the transcription factor forkhead box (Fox)P3, as it
is constitutively expressed at high level in both natural
and adaptive CD4þCD25 þ cells [41]. As the expression of
the surface marker CD127 inversely correlates to that of
Peripheral CD4þ T cells and lung manifestation of SLE 773FoxP3 it can be alternatively used to identify Treg cells
[42]. As previously reported by Yang et al. [43] our data
confirmed decreased Treg cell number in the peripheral
blood of all SLE patients using Treg cell identification
by the combination of CD4þCD25 þ CD127 surface
markers.
Our analysis of the CD4þCD25hiþ cells confirmed
significantly increased number in SLEpulm as compared to
SLEc patients, while no difference in CD4þCD25hiþ CD127
(Treg) cell count was detected. This was the only peripheral
CD4þ cell subtype analyzed to show e even at this small
sample size e a significant difference according lung
involvement in SLE patients and might reflect recent acti-
vation of T lymphocytes. Dolff at al. reported the relative
proportion of FoxP3 in CD4þCD25hiþ cells to be about 80%
in SLE and control groups [44]. The ratio of Treg to
CD4þCD25hiþ cell was 87% in our SLEc and 62% in controls,
but showed significant decrease in our SLEpulm group (15%).
CD4þCD25hiþ lymphocytes of SLE patients produce IL-4
similarly to healthy controls, while significantly decreased
production of interferon gamma and IL-17 were noted in
these cells [44].
The CD4þCD25hiþ cell number and Treg/CD4þCD25hiþ
ratio correlated to all lung function parameters analyzed
pointing out the significance of other than Treg
CD4þCD25hiþ T cell subgroups in the development of lung
involvement in lupus. Diminished number and suppressive
capacity of Treg cells was also shown in patients with other
pulmonary diseases including idiopathic pulmonary fibrosis
and other systemic autoimmune diseases with pulmonary
involvement (rheumatoid arthritis, Sjo¨gren’s syndrome,
systemic sclerosis and SLE patients) [45]. Smoking and
chronic obstructive pulmonary disease increases
CD4þCD25hiþ cells in the bronchoalveolar lavage without
the increase of Tregs, indicating the expansion of a T cell
population without regulatory function [46,47]. More
smokers in the subgroup of SLEpulm might have contributed
to the increase of this T cell subset, however also non-
smokers had higher values in patients with lung
involvement.
In conclusion, high prevalence of lung manifestations in
SLE, especially in older patients was described. Main
respiratory symptom was dyspnea, majority of patients in
the SLEpulm group showed lung function abnormalities
(92%), including decrease in FVC, FEV1, FEF25e75 and DLco
and decrease in pO2 values. As spirometry including DLco
and blood gas analysis is a routine, non invasive, cheap
measurement regular assessment should be performed in
the daily clinical practice especially in patients with pul-
monary complaints to notice pleuropulmonary involve-
ment in time. Changes in Th1/Th2 or Th17/Treg in SLE
patients were observed, however no differences accord-
ing pleuropulmonary manifestations were recorded. In
contrast, our data first described a significant positive
correlation between peripheral CD4þCD25hiþ T cells and
lung function parameters (FVC and FEV1) and DLco indi-
cating that these cells might represent lung specific
immunological activity in SLE. Identification of the
increased non-Treg CD4þCD25hiþ T lymphocyte subtype
might contribute to the better understanding of lung
manifestation development in SLE patients and needs
further investigations.Conflict of interest
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